• 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008

The journal «ONCOSURGERY» 2012, Vol.4, No 4

Chemotherapy in treatment for locally-advanced larynx cancer

Sivkovich OO

Science-clinical center of otolaryngology, FMBA of Russia, Moscow, Russia
Contact: Syvcovich OO, e-mail:

Search for effective methods of larynx cancer treatment is one of the actual challenges in modern oncology. This is caused not only with increased share of larynx cancer and it’s high incidence in the tumors of the upper respiratory tract structure, but also with new requirements for methods of surgical treatment in oncological patients. [3]. Larynx cancer treatment should combine oncological radicalism and possibility of the full rehabilitation of respiratory, speech and separatory function of the organ.

In majority of cases more than 50% reduce of primary tumor size occurred after two courses of neoadjuvant chemotherapy.

Including neoadjuvant chemotherapy with EGFR inhibitor into combined modality treatment plan in patients with locally advanced larynx tumor allows achieving performance of radical and functionally gentle surgery.

The best results were observed in the group with significant sensitivity of tumor cells to chemotherapeutic drugs, where tumor resorption and grade 3-4 treatment pathomorphosis were registered. This demonstrates the ability to create ablastic conditions for organ preservation surgery, while maintaining the boundaries of the primary tumor, considering which the intervention should be carried out.

KEY WORDS: neoadjuvant polychemotherapy, antitumor therapy, larynx cancer, thyroid cartilage.

References

  1. Kanayev S.V. Principles and rationale chemoradiation treatment of malignant tumors. Prakticheskaya onkologiya. 2008; 1: 1-8.
  2. Perevodchikova N.I. Guidelines for chemotherapy of tumors. M.: Prakticheskaya meditsina. 2005. 698.
  3. Reshetov V.I., Chissov V.I., Trofimov Ye.I. Hypopharynx cancer. M.: Meditsina. 2006; 280.
  4. Saleh MN, et al. Combined modality therapy of A431 human epidermoidcancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999; 14: 451-463.
  5. Nasu S, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 2001; 51: 474-477.
  6. Cohen S, et al. Epidermal growth factor-receptor-protein kinase interactions. Copurification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem. 1980; 255: 4834-4842.
  7. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 1935-1940.
  8. Milas L, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004; 58: 966-971.
  9. Schmidt-Ullrich RK, et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene. 2003; 22: 5855-5865.
  10. Kawaguchi Y, et al. Erbitux induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2006; 120: 781-787.
  11. Hadari YR, Doody JF. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. Presented at the 2004 Gastrointestinal Cancers Symposium. San Francisco. 2004; 22-24.

P. 55-53

Publishers
«Oncokhirurgia Info»

10 Vostochnaia ul., suite 16, Moscow, 115280
Tel./fax: +7(499) 426-46-22
Tel.: +7(915) 356-03-07
E-mail:
URL: oncosurgery.oncology.ru


РСХО